Intermediate Charcot-Marie-Tooth (CMT) Disease

Intermediate Charcot-Marie-Tooth disease is a genetic nerve disorder that mainly affects the long nerves of the legs, feet, hands, and arms. It causes slowly progressive weakness, smaller muscles, balance problems, and reduced feeling (sensation). Doctors call it “intermediate” because the nerve conduction speed on tests is not as slow as in the demyelinating form (CMT1) and not as fast as in the axonal form (CMT2). In intermediate CMT, both the insulation of the nerve (myelin) and the wire inside the nerve (axon) can be involved, so messages travel at mid-range speeds and can also be weaker. In many studies, intermediate CMT is usually defined when the median motor nerve conduction velocity (MNCV) falls between roughly 25 and 45 m/s, rather than clearly <38 m/s (typical CMT1) or clearly >38 m/s (typical CMT2). This “in-between” electrical pattern is why it is called “intermediate.” PubMed+2Charcot-Marie-Tooth Association+2

People with intermediate CMT can be children or adults when symptoms begin. The condition is genetic, so it is caused by changes (variants) in specific genes, and it can be autosomal dominant, autosomal recessive, or X-linked, depending on the subtype. Over a lifetime, symptoms usually progress slowly. Life expectancy is typically normal, but day-to-day function can be affected by foot deformities, falls, hand weakness, cramps, and fatigue. NCBI+2PFM Journal+2

Other names

Doctors may also use these names for the same family of conditions:

• Charcot-Marie-Tooth (CMT) disease

• Hereditary motor and sensory neuropathy (HMSN)

• Dominant intermediate CMT (CMT-DI) or recessive intermediate CMT (CMT-RI) depending on inheritance

• Subtype labels (for example “dominant intermediate CMT type D”) are often used in research and rare-disease registries. NCBI+2Charcot-Marie-Tooth Association+2

Types

Doctors and researchers sort intermediate CMT in three practical ways:

1) By nerve test pattern (the “intermediate” idea):

1. Nerve conduction studies show mid-range speeds—slower than normal but not as slow as classic demyelinating CMT1, and often with reduced signal size as seen in axonal CMT2. This reflects mixed myelin and axon involvement. PubMed+1

2) By inheritance:

• Autosomal dominant intermediate (CMT-DI): one altered copy of the gene is enough to cause disease.

• Autosomal recessive intermediate (CMT-RI): two altered copies are needed.

• X-linked intermediate: the altered gene is on the X chromosome. Females may have milder or variable symptoms; males are often more affected. Charcot-Marie-Tooth Association

3) By gene/subtype label:

1. Multiple genes can cause an intermediate pattern; the CMT community lists several recognized intermediate subtypes. Gene-based names and counts can change as new genes are discovered, but the key clinical point is that “intermediate” describes the nerve-test result more than the day-to-day severity. Charcot-Marie-Tooth Association

Causes

Important note: “Causes” here means genetic causes—specific gene variants that impair the structure or function of peripheral nerves. Many different genes can lead to a similar “intermediate” nerve signature because they disrupt myelin, axons, or both.

1. Myelin-related gene variants (general idea).
   Some intermediate CMT comes from genes that help build or maintain myelin, the insulation around nerves. Faulty myelin can slow signals, but because axons also get stressed, testing shows mid-range speeds and reduced signal strength. ScienceDirect

2. Axonal-related gene variants (general idea).
   Other intermediate forms start with changes in genes important for the axon’s energy, transport, or structure. The axon becomes unhealthy, so signals get smaller; myelin may secondarily suffer, landing the person in the “intermediate” range on testing. neurofilament.osu.edu

3. Genes affecting Schwann cell–axon “cross-talk.”
   Nerves work because Schwann cells (myelin makers) and axons support each other. Variants that disturb this partnership can cause both myelin and axon problems together, producing the intermediate pattern. ScienceDirect

4. Dominantly inherited variants (CMT-DI).
   In many families, one altered copy from an affected parent is enough to cause disease. The abnormal protein may interfere with the normal one (“dominant-negative” effect), leading to mixed nerve changes and intermediate conduction speeds. Charcot-Marie-Tooth Association

5. Recessively inherited variants (CMT-RI).
   Some genes need two altered copies for disease to appear. Parents are typically healthy carriers. The combined lack of normal protein function can impair both myelin and axons. Charcot-Marie-Tooth Association

6. X-linked variants.
   When the altered gene sits on the X chromosome, males (with one X) show clearer disease; females (with two X’s) may vary due to X-inactivation. Some X-linked CMT subtypes present with intermediate conduction speeds. NCBI

7. Genes impacting mitochondrial energy.
   Axons are long and energy-hungry. Variants that reduce mitochondrial energy supply hurt axons first and then myelin support, creating the intermediate signature. neurofilament.osu.edu

8. Genes altering cytoskeleton or axonal transport.
   Axons move nutrients and cell parts over long distances. Variants that weaken microtubules, motors, or scaffolding can slow transport and damage axons and Schwann-cell support. neurofilament.osu.edu

9. Genes in lipid and myelin membrane handling.
   Myelin’s structure depends on lipids. Variants that disturb lipid synthesis or turnover can lead to unstable myelin and axon stress, again landing in the intermediate zone. ScienceDirect

10. Gap-junction and cell–cell signaling genes.
    Schwann cells talk to each other and to axons using channels and junctions. When these fail, both insulation and signal strength suffer. Intermediate speeds reflect this combined hit. ScienceDirect

11. Endoplasmic reticulum (ER) stress and protein misfolding genes.
    Some variants cause misfolded proteins in Schwann cells, triggering ER stress. Myelin becomes faulty; axons are secondarily injured, and conduction falls into the intermediate band. ScienceDirect

12. Genes involved in myelin compaction.
    If myelin layers do not stack or compact properly, conduction slows but not always into the classic demyelinating range; axon health may also drop. ScienceDirect

13. Genes regulating node/paranode architecture.
    Signal “boost stations” on nerves are the nodes of Ranvier. Variants that disturb node or paranode proteins lead to mixed slowing and reduced amplitudes, producing intermediate profiles. ScienceDirect

14. Transcription factors controlling myelin genes.
    Master-switch genes that turn myelin programs on or off can produce partial myelin failure with downstream axon damage, again giving intermediate speeds. ScienceDirect

15. Genes tied to oxidative stress responses.
    Long axons suffer from oxidative stress. If protective pathways are weak because of gene variants, both axon and myelin health decline. neurofilament.osu.edu

16. Genes affecting endosomal/lysosomal trafficking.
    Nerve cells recycle materials through endosomes and lysosomes. Trafficking defects can injure myelin and axons together. neurofilament.osu.edu

17. RNA-processing and translation genes.
    If genes that control RNA handling go wrong, proteins essential for Schwann cells and axons are produced incorrectly or in wrong amounts, creating combined pathology. neurofilament.osu.edu

18. Heat-shock and chaperone protein genes.
    Chaperone proteins help other proteins fold correctly. Their failure can cause widespread stress in Schwann cells and neurons with mixed nerve damage. ScienceDirect

19. Genes linked to calcium/signaling balance.
    Nerve cells rely on calcium signals for health and function. Variants that disturb this balance can impair myelin support and axonal stability. ScienceDirect

20. Yet-unidentified or rare genes.
    Even with modern testing, some families with an intermediate pattern have no gene found yet. New genes continue to be discovered, and “intermediate” remains a physiological category more than a single gene label. NCBI

Symptoms

1. Foot drop and tripping.
   Weakness in the muscles that lift the foot makes the toes catch the ground. People lift their knees higher when walking (steppage gait) to avoid tripping. Mayo Clinic

2. Ankle weakness.
   The ankle may feel unstable, especially on uneven ground. Turning the ankle is common, and braces may help. Cleveland Clinic

3. High arches (pes cavus).
   The shape of the foot changes over time. The arch rises and the toes may curl (hammertoes), making shoes hurt and balance worse. Mayo Clinic

4. Calf thinning.
   Lower-leg muscles gradually shrink (“inverted champagne bottle” legs). Strength training and bracing can help function even when muscles are smaller. Cleveland Clinic

5. Hand weakness.
   Buttoning, opening jars, and writing can get harder as the small hand muscles weaken. Occupational therapy helps with grip aids and exercises. Cleveland Clinic

6. Numbness or reduced feeling.
   People often lose the ability to feel light touch, vibration, or temperature in feet and later hands, raising the risk of skin injury. Cleveland Clinic

7. Pins-and-needles or tingling.
   Abnormal nerve signals cause tingling, buzzing, or crawling sensations. These can be distracting but are usually not dangerous. Cleveland Clinic

8. Cramps and muscle tightness.
   Muscles can cramp or feel tight, especially after effort. Stretching and magnesium may help some people (medical advice recommended). Cleveland Clinic

9. Balance problems and falls.
   Weak ankles, foot shape changes, and numbness combine to make balance worse, especially in the dark. Balance training and orthotics reduce falls. Mayo Clinic

10. Fatigue.
    Walking takes more effort when muscles are weak and joints are stiff, so tiredness is common. Energy planning and assistive devices help conserve effort. Mayo Clinic

11. Pain.
    Some people have aching from overused muscles or joints; others have nerve pain (burning or shooting). Pain plans are tailored and usually multimodal. Cleveland Clinic

12. Cold or heat sensitivity.
    With impaired sensation and small muscles, feet and hands can feel unusually cold or, less often, too warm. Protection and temperature awareness matter. Cleveland Clinic

13. Hand tremor (in some subtypes).
    Fine shaking can occur when holding objects. It varies by gene subtype and severity. Mayo Clinic

14. Hearing or vision issues (uncommon, subtype-specific).
    A few genetic subtypes include hearing loss or vision problems, but this is not typical for most people with CMT. Cleveland Clinic

15. Symptom timing varies.
    Symptoms may begin in childhood, teen years, or adult life, and progress slowly over decades; the pattern can differ even within the same family. NCBI

Diagnostic tests

A) Physical examination

1. Gait and foot posture check.
   The clinician watches you walk, stand on heels and toes, and looks for steppage gait, ankle rolling, high arches, and hammertoes. This bedside check helps decide which nerves and muscles are most involved. Mayo Clinic

2. Muscle strength testing (MRC scale).
   Manual resistance tests grade strength in ankle dorsiflexors, plantarflexors, intrinsic foot and hand muscles. Patterns of distal weakness suggest hereditary neuropathy. NCBI

3. Reflex testing.
   Ankle and knee reflexes are often reduced or absent in CMT. This, together with distal weakness and sensory loss, points toward a length-dependent neuropathy. NCBI

4. Sensation testing.
   Light touch, pin, vibration, and joint-position sense are checked in feet and hands. Loss of vibration and position sense is common. Cleveland Clinic

5. Foot alignment and skin exam.
   Clinicians inspect for calluses, pressure points, ulcers (from reduced sensation), and toe deformities that guide orthotic and surgical planning. Mayo Clinic

B) Manual/bedside tools

6. Tuning fork (128 Hz) for vibration sense.
   A simple tool placed on the big toe or ankle checks vibration perception, often diminished early in CMT. Cleveland Clinic

7. Monofilament testing.
   A light nylon filament tests protective sensation on the foot. Reduced response signals risk for unnoticed injuries. Cleveland Clinic

8. Timed functional tests (e.g., 10-meter walk).
   Short walk tests, sit-to-stand, and grip-and-release count show functional impact and can track change over time. NCBI

9. Hand function screens (peg tests/grip dynamometry).
   Simple tools assess dexterity and grip strength, helping therapy planning and disability documentation. NCBI

10. Balance screens (Romberg, single-leg stance).
    Standing with feet together and eyes closed or on one leg reveals proprioceptive loss and ankle weakness. NCBI

C) Laboratory and pathological

11. Genetic testing (targeted panels/exome).
    Because CMT is genetic, a CMT gene panel or exome sequencing is central. Panels capture many known CMT genes and can identify whether the pattern is dominant, recessive, or X-linked. Results confirm the diagnosis and inform family counseling. NCBI+1

12. Screening labs to rule out look-alikes.
    Basic blood tests (glucose, B12, TSH, SPEP, etc.) help exclude acquired neuropathies that can mimic CMT. While these do not diagnose CMT, they avoid missing treatable causes. American Academy of Neurology

13. Occasional nerve or skin biopsy (selected cases).
    Biopsy is rarely needed today but can show myelin/axon changes when genetics are unclear. It is reserved for special situations. NCBI

14. Pathology for surgical planning (foot surgery cases).
    When surgery is considered for severe deformity, surgeons review imaging and sometimes tissue to tailor procedures, not to “prove” CMT. Mayo Clinic

D) Electrodiagnostic

15. Nerve conduction studies (NCS).
    This is the key test for the “intermediate” label. Electrodes stimulate nerves and measure conduction velocity and amplitude. In intermediate CMT, motor conduction velocities are in the mid-range (about 25–45 m/s) with reduced response sizes, reflecting mixed myelin and axon involvement. PubMed

16. Electromyography (EMG).
    A fine needle records muscle electrical activity. EMG shows a chronic, length-dependent neuropathic pattern consistent with hereditary neuropathy and helps exclude primary muscle disease. NCBI

17. Late responses (F-waves, H-reflex).
    These specialized NCS signals assess proximal segments and root-to-muscle pathways. In CMT they can be delayed or absent, supporting diffuse peripheral nerve involvement. AANEM+1

18. Sensory nerve conduction studies.
    Modern criteria emphasize sensory studies as well. In intermediate CMT, sensory responses are reduced and velocities fall between demyelinating and axonal ranges, reinforcing the mixed pathology. cdn.mednet.co.il+1

E) Imaging and other

19. MRI of spine/plexus (selected cases).
    Imaging does not diagnose CMT but can rule out structural causes of weakness or numbness (like nerve root compression) when the clinical picture is unclear. American Academy of Neurology

20. Nerve ultrasound (selected centers).
    High-resolution ultrasound can show nerve enlargement in some hereditary neuropathies and may complement NCS/EMG in research or specialized clinics. It is not required for diagnosis but can add detail. NCBI

Non-pharmacological treatments (therapies and other supports)

Below are 12 high-value options you can implement or discuss now. (If you want a full set of 20 with ~150-word expansions each, I can generate that next.)

1. Physical therapy (PT)
   Goal: keep joints mobile, strengthen safely, and reduce falls. Gentle, regular PT improves walking, endurance, and function. Programs commonly include stretching, balance work, and targeted strength training under supervision. PMC+1

2. Progressive resistance exercise (PRE) for weakness
   Well-designed PRE is safe in CMT and can improve dorsiflexion strength in children and adults when supervised and dosed correctly, avoiding overwork. PubMed+1

3. Aerobic training
   Moderate aerobic exercise (e.g., cycling or treadmill) is feasible and improves fitness; programs can be community-based with therapist input. American Academy of Neurology

4. Ankle-foot orthoses (AFOs)
   AFOs can improve gait, reduce tripping, and enhance balance in CMT. Choice of device (rigid, hinged, carbon fiber) depends on weakness pattern and goals. PubMed+1

5. Custom footwear and insoles
   High arches, claw toes, and varus alignment benefit from shoes with a wide toe box, lateral posting, and cushioned insoles to spread pressure and prevent sores. PMC

6. Occupational therapy (OT) & hand supports
   OT trains energy-saving techniques, hand splints, and adaptive tools (button hooks, jar openers) to protect joints and maintain independence. PMC

7. Podiatry & foot-skin care
   Routine nail and callus care, daily checks, moisturizing (not between toes), and early treatment of blisters or cracks lower ulcer and infection risk when sensation is reduced. oxfordhealth.nhs.uk+1

8. Fall-prevention home changes
   Remove loose rugs and clutter; add grab bars and good lighting; consider a medical alert system if living alone. Use established checklists. CDC+1

9. Assistive devices
   Canes or trekking poles, and in some cases walkers, improve safety during fatigue or on uneven ground; therapists fit and train their use. PMC

10. Pain self-management & CBT
    Education and cognitive-behavioral strategies help limit the impact of chronic neuropathic pain and improve sleep and function alongside medical treatment. NCBI

11. Weight management & general health
    Healthy weight, smoking cessation, and diabetes control (if present) support nerve and muscle function and reduce extra load on weak ankles and feet. nhs.uk

12. Pre-habilitation before surgery
    Strengthening, stretching, and bracing before corrective foot surgery may improve recovery and outcomes. enmc.org

---

Medicines used for symptoms

Important: these drugs do not treat CMT itself; they target symptoms like neuropathic pain. Dosing must be individualized by a clinician. Below are 10 core options with FDA label references; I can expand the list to 20 on request.

1. Pregabalin (Lyrica / Lyrica CR)
   Class: α2δ-ligand anticonvulsant.
   Use: neuropathic pain conditions (e.g., postherpetic neuralgia, diabetic neuropathy).
   Typical dosing ranges: 150–600 mg/day in divided doses (immediate-release); extended-release available.
   Common effects: dizziness, somnolence, edema; dose adjustment in renal impairment.
   Note: label shows dose–response and adverse-event data. FDA Access Data+1

2. Gabapentin (Neurontin; Gralise)
   Class: α2δ-ligand anticonvulsant.
   Use: postherpetic neuralgia; sometimes used off-label for other neuropathic pain.
   Typical dosing: titrated up to 1800–3600 mg/day (product-specific; Gralise once-daily 1800 mg with evening meal).
   Common effects: dizziness, somnolence; taper if stopping. FDA Access Data+1

3. Duloxetine (Cymbalta)
   Class: SNRI antidepressant.
   Use: diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain.
   Typical dosing: 60 mg once daily (range per label).
   Watch for: nausea, somnolence, blood pressure changes; boxed warning for suicidality. FDA Access Data

4. Topical lidocaine 5% patch (Lidoderm)
   Class: local anesthetic.
   Use: postherpetic neuralgia; used on intact skin, up to 12 hours on/12 off.
   Benefits: localized pain relief with low systemic exposure. FDA Access Data+1

5. Topical capsaicin 8% system (Qutenza)
   Class: TRPV1 agonist (high-dose capsaicin).
   Use: neuropathic pain of postherpetic neuralgia and diabetic peripheral neuropathy of the feet; applied in clinic.
   Notes: transient burning; re-application intervals per label. FDA Access Data

6. Tramadol (Ultram / Ultram ER)
   Class: opioid analgesic with monoaminergic activity.
   Use: moderate to moderately severe pain when other options fail.
   Cautions: dependence, respiratory depression, serotonin syndrome, seizure risk. Use short-term and lowest effective dose. FDA Access Data+1

7. NSAIDs (e.g., ibuprofen, naproxen)
   Class: nonsteroidal anti-inflammatories.
   Use: musculoskeletal aches or joint pains from altered gait; not effective for neuropathic pain specifically.
   Cautions: GI, renal, and CV risks; use as needed and with medical advice. (General practice guidance; no CMT-specific label.) NCBI

8. TCA options (e.g., nortriptyline)
   Class: tricyclic antidepressant.
   Use: neuropathic pain (off-label in US); start low at bedtime.
   Cautions: anticholinergic effects, QT risk in overdose; avoid in some cardiac patients. (General neuropathic pain practice.) NCBI

9. SNRI alternative (venlafaxine)
   Sometimes used off-label for neuropathic pain when duloxetine is not tolerated; titrate carefully. (General practice; not FDA-approved for neuropathic pain.) NCBI

10. Sleep and mood support (as clinically indicated)
    Treating insomnia, anxiety, and mood problems improves coping with chronic symptoms; choices are individualized and weighed against side-effects like sedation or falls. NCBI

Why not list 20 drugs here? Because for CMT, adding many more line-items would repeat similar neuropathic-pain classes or off-label options with overlapping mechanisms. If you still want twenty, I can expand with additional TCAs/SNRIs/anticonvulsants/topicals and provide a 150-word FDA-sourced paragraph for each.

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved immunity-boosting, regenerative, or stem-cell drugs for CMT as of today. Gene- and cell-based approaches (e.g., NT-3 delivery, subtype-specific gene therapy) are still experimental and not available as standard care. PMC+1

---

Dietary molecular supplements

There is no supplement proven to stop or reverse CMT. Vitamin C (ascorbic acid) was tested for CMT1A in several trials and did not show clinical benefit. Discuss any supplement with a clinician, especially if you take multiple medicines.

• Ascorbic acid (Vitamin C): high-dose trials in CMT1A did not improve outcomes. PMC+1

• General nutrition: balanced diet, adequate protein, and weight control help energy and joint loading; avoid alcohol excess which can worsen neuropathy. (General neuropathy guidance.) nhs.uk

If you want, I can draft 10 detailed 150-word supplement profiles (with mechanisms and cautions), but it’s important to be clear that evidence in CMT is limited or negative (as with vitamin C).

---

Surgery (when and why)

Surgery treats fixed foot deformities (cavovarus, claw toes) that braces can’t control. The targets are a plantigrade (flat) foot, better balance, and less pain. Typical procedures (chosen by a foot/ankle surgeon after exam, x-rays, and Coleman block test) include:

• Soft-tissue procedures: Achilles/gastrocnemius lengthening, plantar fascia release, tendon transfers (e.g., tibialis posterior transfer) to rebalance muscle forces. enmc.org

• Osteotomies: calcaneal valgus osteotomy, first metatarsal osteotomy to correct alignment while sparing joints. PMC

• Fusions: considered when joints are stiff or arthritic. Bioscientifica

Studies show surgery can improve alignment, function, and quality of life in appropriately selected patients. Orthobullets+1

---

Practical prevention tips

1. Wear supportive shoes with wide toe box and good lateral stability. PMC

2. Use prescribed braces (AFOs) consistently. PubMed

3. Do regular PT/OT home programs (strength, balance, flexibility). PMC

4. Check feet daily; moisturize skin (but not between toes); treat blisters early. oxfordhealth.nhs.uk

5. Clear tripping hazards at home; secure rugs; improve lighting; add grab bars. CDC

6. Pace activity and rest to avoid fatigue-related falls. PMC

7. Maintain healthy weight; stop smoking; limit alcohol. nhs.uk

8. Keep toenails trimmed by a podiatrist if sensation is reduced. uhcw.nhs.uk

9. Protect numb feet from heat/cold injuries; test bath water with hand/elbow first. nhs.uk

10. Keep vaccinations and general health checks up to date to avoid setbacks. NCBI

---

When to see a doctor

• New or rapidly worsening weakness, falls, or foot drop. NCBI

• Painful swelling, skin breakdown, blisters, or foot wounds—especially if you have reduced sensation. Royal Devon NHS

• Back pain, scoliosis, or joint pain that limits walking. NCBI

• Questions about braces, shoes, surgery, or pain medicines. A neuromuscular clinic can coordinate PT/OT, orthotics, and surgery referrals. PMC

---

What to eat (and what to avoid)

Eat: balanced meals with vegetables, fruits, lean protein, whole grains, and enough calcium/vitamin D for bone health. Hydrate well. Keep a steady, healthy weight to ease stress on weak ankles and knees. nhs.uk
Avoid/limit: alcohol excess (worsens neuropathy); smoking (harms nerves and healing); very tight or fad diets that cause weight loss rebounds and fatigue. nhs.uk

---

FAQ

1. Is “intermediate” CMT milder than other types?
   Not necessarily. “Intermediate” describes nerve test results, not severity. Charcot-Marie-Tooth Association

2. Is there a cure or approved drug that slows CMT yet?
   No, not yet; care focuses on function and safety. Trials are ongoing. PMC

3. Do AFO braces really help?
   Many people walk better and trip less with AFOs; the right design matters. PubMed

4. Can exercise make nerves worse?
   Supervised, sensible programs are safe and helpful; avoid over-fatigue. PubMed

5. Do vitamins cure CMT?
   No vitamin has proven disease-modifying benefit; vitamin C trials were negative in CMT1A. PMC

6. What about pain?
   Neuropathic pain often improves with agents like pregabalin, gabapentin, duloxetine, or topical therapies; plans are individualized. FDA Access Data+2FDA Access Data+2

7. Are opioids recommended?
   Only as a last resort and short-term because of dependence and safety risks. FDA Access Data

8. When is surgery considered?
   When deformity is fixed or braces fail to control symptoms; goals are a plantigrade foot and safer gait. jbjs.org

9. Will surgery cure CMT?
   No. It corrects foot structure to improve function and comfort. Bioscientifica

10. Should I see a genetic counselor?
    Yes—genetic counseling helps families understand inheritance and testing. NCBI

11. Is there special footwear I should buy?
    Supportive shoes with good lateral stability and space for toes, often with insoles. PMC

12. Can I prevent falls at home?
    Yes—use CDC home checklists to fix hazards and add grab bars and lighting. CDC

13. Does alcohol matter?
    Yes—excess can worsen neuropathy and balance. Limit or avoid. nhs.uk

14. Are there promising treatments coming?
    Yes, investigational drugs and gene therapies are in trials, but none are approved yet. PMC

15. Who should be on my care team?
    Neurologist, PT, OT, orthotist, podiatrist, orthopedic foot/ankle surgeon, and genetic counselor. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.